Optipharm produces transgenic animals for xenotransplantation
by ensuring that specific genes are accurately removed or stably
Research VLP VACCINE
We research how to manufacture vaccine antigens based on virus-like
particles (VLP vaccine), a technology that is expected to increase the
stability and immune effect, which have been problematic in existing
The phage division of Optipharm Co., Ltd. uses bacteriophages whose host is
bacteria as an alternative to antibiotics to solve the problem of infectious
diseases caused by antibiotic-resistant bacteria.
Highlight Optipharm records by the numbers
A leader in supporting human welfare
through the recreation of the value of life
Xenotransplantation is a process undertaken to resolve the problem of organ shortage, in which organs, tissues,
or cells from the animal of one species are transplanted to an animal of another species.
Preparation of a safe vaccine antigen
without the capacity for infectivity and proliferation
With insect cell based VLP vaccine antigen production technology (OptiVLP™), we established a system in which it takes less than six months to complete a process spanning from selecting target genes to securing seeds for vaccine production.
Safely and effectively
removes pathogenic bacteria
We secured about 400 excellent bacteriophages that are effective against pathogenic bacteria,
applied for a patent, and carried out a number of studies, which ultimately led to a successful
commercialization of bacteriophage products.
‘Useful life resource’
By approaching the issue from a range of
perspectives, we are making a more
professional and accurate diagnosis of
Medipig We provide animal models for biological and medical research for the treatment of incurable human diseases
Through the research and development of miniature pigs,
we are mainly involved in the sale of miniature pigs for
laboratory animals and contract research organization (CRO)
to contribute to the improvement of human health and welfare.
06 30[Update] The paper on the development of transgenic animals _ Scientific Reports
Hello, OptiPharm's homepage.administrator. The paper on the development of transgenic animals has been finally approved for publication in Scientific Reports, a sister magazine of the Nature journal, and we are informing you as follows.- A desirable transgenic strategy using GGTA1 endogenous promoter-medicated knock‑in for xenotransplantation model- Related Links: https://www.nature.com/articles/s41598-022-13536-z.pdf
03 16Opening a new website
Hello, We are currently preparing to open a new website. We will do our best to open as soon as possible. Thank you.